Immatics CMO Cedrik M. Britten will present clinical data on TCR T-cell therapy and bispecific T-cell engagers targeting PRAME+ cancers at the SITC EU Immuno-Oncology Drug Development Summit on September 3, 2026.
Published
Signal category
Presence & Recognition
Quote
“This week at the SITC EU Immuno-Oncology Drug Development Summit, CMO, Cedrik M. Britten, will present clinical data on TCR T-cell therapy and bispecific T-cell engagers targeting PRAME+ cancers”
— Immatics team
Company
Immatics
The Global Leader in Precision Targeting of PRAME
- Industry
- Biotechnology Research
- Location
- Tuebingen, DE
- Company size
- 652 employees
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
Founded 2000